Results 91 to 100 of about 5,563 (240)

Engineered neutrophil engagers overcome IgA limitations and reprogram resting neutrophils for cancer immunotherapy

Journal of Biological Engineering
Background Bispecific antibodies that redirect T cells or NK cells to tumors have demonstrated substantial therapeutic efficacy, but their broader application is often constrained by immune-related toxicities, limited effector cell availability, and ...
Jisun Lee, Garam Han, Munsu Kyung, Seunghyeon Lee, Tae Woo Kim, Sang Taek Jung   +5 more
doaj   +1 more source

The T‐Cell Response Mechanism in Human Papillomavirus‐Associated Cervical Cancer and New Strategies for Immunotherapy

iNew Medicine, EarlyView.
ABSTRACT Human papillomavirus (HPV) is a double‐stranded DNA virus that infects human skin and mucosal tissues exclusively. The German scientist Harald zur Hausen was awarded the 2008 Nobel Prize in Physiology or Medicine for his discovery of the link between HPV infection and cervical cancer.
Fang Zhu, Farah Nazir, Ying Zhou, Yuhua Shang, Hongliang He, Tengchuan Jin   +5 more
wiley   +1 more source

Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion

Frontiers in Oncology
BackgroundVγ9Vδ2 T-cells are antitumor immune effector cells that can detect metabolic dysregulation in cancer cells through phosphoantigen-induced conformational changes in the butyrophilin (BTN) 2A1/3A1 complex.
Lisa A. King, Lisa A. King, Lisa A. King, Milon de Jong, Milon de Jong, Milon de Jong, Myrthe Veth, Myrthe Veth, Myrthe Veth, David Lutje Hulsik, Parsa Yousefi, Victoria Iglesias-Guimarais, Pauline M. van Helden, Tanja D. de Gruijl, Tanja D. de Gruijl, Tanja D. de Gruijl, Hans J. van der Vliet, Hans J. van der Vliet, Hans J. van der Vliet   +18 more
doaj   +1 more source

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies

Frontiers in Immunology, 2020
Bispecific antibodies (BsAbs) are designed to recognize and bind to two different antigens or epitopes. In the last few decades, BsAbs have been developed within the context of cancer therapies and in particular for the treatment of hematologic B-cell ...
Margaux Lejeune, Murat Cem Köse, Elodie Duray, Hermann Einsele, Yves Beguin, Yves Beguin, Jo Caers, Jo Caers   +7 more
doaj   +1 more source

Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer. [PDF]

Cancer
Tarlatamab is a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation 3 (CD3) molecule. In the phase 2 DeLLphi-301 trial of tarlatamab for patients with previously treated small cell lung cancer ...
Sands JM, Champiat S, Hummel HD, Paulson KG, Borghaei H, Alvarez JB, Carbone DP, Carlisle JW, Choudhury NJ, Clarke JM, Gadgeel SM, Izumi H, Navarro A, Lau SCM, Lammers PE, Huang S, Hamidi A, Mukherjee S, Owonikoko TK.   +18 more
europepmc   +2 more sources

Potent monoclonal antibodies against multidrug‐resistant hypervirulent Klebsiella pneumoniae

Interdisciplinary Medicine, EarlyView.
A novel immunization strategy using a low‐virulence, multidrug‐resistant strain yields synergistic monoclonal antibodies against hypervirulent Klebsiella pneumoniae. These antibodies provide cross‐serotype protection through a dual‐mechanism of pathogen clearance and immunomodulation, offering a promising non‐antibiotic therapeutic for resistant ...
Yushan Jiang, Zhuolin Li, Yang Yang, Zihan He, Tyuji Hoshino, Vladislav Victorovich Khrustalev, Qing Zhu, Weiling Wu, Wei Zhao, Chenguang Shen, Shi Ouyang   +10 more
wiley   +1 more source

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies

EMBO Molecular Medicine, 2017
Oncolytic viruses exploit the cancer cell phenotype to complete their lytic life cycle, releasing progeny virus to infect nearby cells and repeat the process.
Joshua D Freedman, Joachim Hagel, Eleanor M Scott, Ioannis Psallidas, Avinash Gupta, Laura Spiers, Paul Miller, Nikolaos Kanellakis, Rebecca Ashfield, Kerry D Fisher, Margaret R Duffy, Leonard W Seymour   +11 more
doaj   +1 more source

Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110. [PDF]

PLoS ONE, 2015
Bispecific T cell engager (BiTE®) are single-chain bispecific antibody constructs with dual specificity for CD3 on T cells and a surface antigen on target cells.
Wibke Deisting, Tobias Raum, Peter Kufer, Patrick A Baeuerle, Markus Münz   +4 more
doaj   +1 more source

Recent Advances (2023–2025) of Capillary Electrophoresis‐Mass Spectrometry (CE‐MS) for Top‐Down Proteomics

Mass Spectrometry Reviews, EarlyView.
ABSTRACT Top‐down proteomics (TDP) characterizes proteoforms in cells, tissues, and biofluids, in discovery mode and on a global scale, requiring analytical tools with high peak capacity for proteoform separation and high sensitivity for proteoform detection, given the extremely high proteoform complexity and wide proteoform concentration dynamic range.
Guijie Zhu, David A. Alvarez Rodriguez, Noah Gould, Alexander R. Ivanov, Kevin Jooß, Liangliang Sun   +5 more
wiley   +1 more source

Fatigue in Myasthenia Gravis: Recent Advances and Emerging Concepts

Muscle &Nerve, EarlyView.
ABSTRACT Fatigue is a common, often disabling symptom in myasthenia gravis (MG), distinct from muscle fatigability, and strongly associated with reduced quality of life. This narrative review examines current evidence on fatigue in MG, its patient impact, and future research directions. Earlier studies, mostly small and heterogeneous, reported a highly
Yvonne J. M. Campman, Martijn R. Tannemaat, Annabel M. Ruiter, Sarah Hoffmann   +3 more
wiley   +1 more source